## QIBA (proposed) SPECT Biomarker Committee Friday, April 17, 2014, 9 AM (CT)

**Draft Call Summary** 

Julie Lisiecki

In attendance: RSNA
Richard Wahl, MD (Moderator) Michael Lassmann, PhD Joe Koudelik

Anna Celler, PhD Manuela Matesan, MD, PhD Eric Perlman, MD
Yuni Dewaraja, PhD Robert Miyaoka, PhD John Seibyl, MD
Brian Hutton, PhD P. David Mozley, MD Anne M. Smith, PhD
Edward F. Jackson, PhD Aaron Nelson, MD Eli Stern, BSc, MBA

Paul Kinahan, PhD, FIEEE Nancy Obuchowski, PhD Benjamin M. W. Tsui, PhD Michael King, PhD, DABR Amy Perkins, PhD Brian Zimmerman, PhD

Moderator: Dr. Richard Wahl

## **Discussion Topics**

- Dr. Dewaraja summarized the data on organ dosimetry with Tc99m, in part based on her work on the MIRD committee.
- Dr. Kinahan gave an overview of the Quantitative SPECT domain as a potential "biomarker" per QIBA biomarker criteria definitions
- Feedback was requested from the group so that a proposal may be brought to the May 5<sup>th</sup> QIBA Steering Committee Meeting. RSNA Staff will re-distribute the draft request for SPECT biomarker status for review.
- Determining answers to some of the following questions will be helpful:
  - What are the commonalities across the two sub-claims (within DaTscan for small organs and dosimetry for large tumors)?
  - What kind or groundwork projects are needed based on technical knowledge gaps identified within the literature?
  - Will there be a common measurand to encompass both sub-claims?
  - o How will confidence intervals around the selected measurements be determined?
  - Could phantom utility play a role in determining applications across other tracers?
- Regarding biomarker committee organization: This will be a volunteer effort, and commitment from participants will be needed for its success.
  - O Who will lead this effort?
    - Three co-chairs for the group would be desirable: one each from academia, clinical work, and industry.
  - O Who will act as Profile Editor?
  - Use-cases need to be identified
  - Any interested parties are asked to contact Drs. Kinahan, Perlman, or Wahl: kinahan@uw.edu; ericsperlman@gmail.com; wahlr@mir.wustl.edu

## Proposed May Nuclear Medicine Calls (Fridays, 9 am CT):

- May 1: FDG-PET Biomarker Ctte
- May 8: No call (day after the QIBA Annual Meeting)
- May 15: Combined Nuclear Medicine Call Update (FDG-PET, Amyloid, SPECT (?))
- May 22: Amyloid Biomarker Ctte
- May 29: (proposed) SPECT Biomarker Ctte

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible Call participants are welcome to contact RSNA staff at <a href="QIBA@RSNA.org">QIBA@RSNA.org</a> if their attendance is not reflected on the call summaries. <a href="QIBA@RSNA.org">QIBA wiki</a>